---
title: "Ovarian Cancer Clinical Trials in California"
description: "Find 715 clinical trials for ovarian cancer near California. Connect with research centers in your area."
url: "https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer/california"
---

# Ovarian Cancer Clinical Trials in California

Find 715 clinical trials for ovarian cancer near California. Connect with research centers in your area.

- [All Ovarian Cancer trials nationwide](https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer)
- [All trials in California](https://www.clareohealth.com/clinical-trials/location/california)

Showing 1-20 of 715 trials

### [A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women](https://www.clareohealth.com/clinical-trials/NCT01121640)

Status: COMPLETED · Phase: NA · NCT01121640 · Duarte, California and 4 others · Sponsor: Fred Hutchinson Cancer Center

The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either…

### [Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer](https://www.clareohealth.com/clinical-trials/NCT00003624)

Status: TERMINATED · Phase: PHASE2 · NCT00003624 · Orange, California and 7 others · Sponsor: Gynecologic Oncology Group

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

### [A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations](https://www.clareohealth.com/clinical-trials/NCT07038369)

Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · NCT07038369 · Los Angeles, California and 7 others · Sponsor: Atavistik Bio, Inc

This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/H…

### [AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)](https://www.clareohealth.com/clinical-trials/NCT01281254)

Status: TERMINATED · Phase: PHASE3 · NCT01281254 · Los Angeles, California and 105 others · Sponsor: Amgen

To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS) The hypothesis for this study is…

### [Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer](https://www.clareohealth.com/clinical-trials/NCT03939481)

Status: ACTIVE_NOT_RECRUITING · NCT03939481 · Antioch, California and 168 others · Sponsor: SWOG Cancer Research Network

This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer.

### [Patient Reported Symptoms in Ovarian Cancer (PRECISION)](https://www.clareohealth.com/clinical-trials/NCT01422265)

Status: COMPLETED · NCT01422265 · Goodyear, Arizona and 30 others · Sponsor: Genentech, Inc.

This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary…

### [Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer](https://www.clareohealth.com/clinical-trials/NCT06463028)

Status: RECRUITING · Phase: PHASE2 · NCT06463028 · La Jolla, California and 17 others · Sponsor: Faeth Therapeutics

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advan…

### [Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer](https://www.clareohealth.com/clinical-trials/NCT00004064)

Status: UNKNOWN · Phase: PHASE2 · NCT00004064 · Newport Beach, California and 15 others · Sponsor: AltaRex

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

### [Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)](https://www.clareohealth.com/clinical-trials/NCT00635193)

Status: COMPLETED · Phase: PHASE1/PHASE2 · NCT00635193 · Anaheim, California and 38 others · Sponsor: AbbVie (prior sponsor, Abbott)

This is an open-label study of liposomal doxorubicin with or without volociximab for the treatment of subjects with advanced epithelial ovarian cancer or primary peritoneal cancer…

### [Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers](https://www.clareohealth.com/clinical-trials/NCT05041257)

Status: COMPLETED · Phase: PHASE2 · NCT05041257 · Duarte, California and 34 others · Sponsor: AbbVie

PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive…

### [Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer](https://www.clareohealth.com/clinical-trials/NCT00719212)

Status: COMPLETED · Phase: PHASE2 · NCT00719212 · Bakersfield, California and 36 others · Sponsor: Translational Research in Oncology

The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallo…

### [Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer](https://www.clareohealth.com/clinical-trials/NCT04606914)

Status: RECRUITING · Phase: PHASE2 · NCT04606914 · Birmingham, Alabama and 8 others · Sponsor: University of Alabama at Birmingham

The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC.

### [REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1](https://www.clareohealth.com/clinical-trials/NCT05870748)

Status: TERMINATED · Phase: PHASE2/PHASE3 · NCT05870748 · Tucson, Arizona and 62 others · Sponsor: Sutro Biopharma, Inc.

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritone…

### [Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors](https://www.clareohealth.com/clinical-trials/NCT05797168)

Status: RECRUITING · Phase: PHASE1/PHASE2 · NCT05797168 · Duarte, California and 59 others · Sponsor: AstraZeneca

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has…

### [Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors](https://www.clareohealth.com/clinical-trials/NCT04774952)

Status: COMPLETED · Phase: PHASE1 · NCT04774952 · Irvine, California and 7 others · Sponsor: Revolution Medicines, Inc.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult part…

### [Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer](https://www.clareohealth.com/clinical-trials/NCT00628251)

Status: COMPLETED · Phase: PHASE2 · NCT00628251 · Los Angeles, California and 23 others · Sponsor: AstraZeneca

The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating pat…

### [Ovarian Cancer Vaccine for Patients in Remission](https://www.clareohealth.com/clinical-trials/NCT01068509)

Status: COMPLETED · Phase: PHASE2 · NCT01068509 · Greenbrae, California and 17 others · Sponsor: Prima BioMed Ltd

The purpose of this study is to determine the safety and efficacy of an investigational therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to dete…

### [Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer](https://www.clareohealth.com/clinical-trials/NCT02059265)

Status: TERMINATED · Phase: PHASE2 · NCT02059265 · Anchorage, Alaska and 226 others · Sponsor: National Cancer Institute (NCI)

This phase II trial studies how well dasatinib works in treating patients with ovarian, fallopian tube, endometrial, or peritoneal cancer that has come back or is persistent.

### [Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer](https://www.clareohealth.com/clinical-trials/NCT00407563)

Status: COMPLETED · Phase: PHASE2 · NCT00407563 · Little Rock, Arkansas and 10 others · Sponsor: Accelerated Community Oncology Research Network

The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer…

### [A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors](https://www.clareohealth.com/clinical-trials/NCT05001347)

Status: COMPLETED · Phase: PHASE2 · NCT05001347 · Tucson, Arizona and 14 others · Sponsor: I-Mab Biopharma US Limited

This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.

## Ovarian Cancer Trials in Other Cities

- [New York](https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer/new-york)
- [Los Angeles](https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer/los-angeles)
- [Chicago](https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer/chicago)
- [Houston](https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer/houston)
- [Phoenix](https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer/phoenix)
- [Philadelphia](https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer/philadelphia)

## Other Conditions in California

- [Breast Cancer](https://www.clareohealth.com/clinical-trials/condition/breast-cancer/california)
- [Lung Cancer](https://www.clareohealth.com/clinical-trials/condition/lung-cancer/california)
- [Prostate Cancer](https://www.clareohealth.com/clinical-trials/condition/prostate-cancer/california)
- [Colorectal Cancer](https://www.clareohealth.com/clinical-trials/condition/colorectal-cancer/california)
- [Melanoma](https://www.clareohealth.com/clinical-trials/condition/melanoma/california)
- [Leukemia](https://www.clareohealth.com/clinical-trials/condition/leukemia/california)

Data from [ClinicalTrials.gov](https://clinicaltrials.gov).

---

## Sitemap

This is the Markdown version of https://www.clareohealth.com/clinical-trials/condition/ovarian-cancer/california.

- [Home](https://www.clareohealth.com/index.md)
- [About](https://www.clareohealth.com/about.md)
- [Pricing](https://www.clareohealth.com/pricing.md)
- [For providers](https://www.clareohealth.com/providers.md)
- [FAQ](https://www.clareohealth.com/faq.md)
- [Blog](https://www.clareohealth.com/blog.md)
- [Clinical trials](https://www.clareohealth.com/clinical-trials.md)
- [Developers](https://www.clareohealth.com/developers.md)
- [Privacy policy](https://www.clareohealth.com/legal/privacy-policy.md)
- [Terms of service](https://www.clareohealth.com/legal/terms-of-service.md)
- [Every page](https://www.clareohealth.com/sitemap.md)
- [About this site, for agents](https://www.clareohealth.com/llms.txt)
